By Fineline Cube Hangzhou-based HealZen Therapeutics Protein Degradation Hisun Pharmaceutical Co., Ltd. a has formed a strategic partnership with compatriot firm Zhejiang Hisun Pharmaceutical Co., Ltd. to jointly develop a first-in-class protein degradation product. The collaboration involves shared research and development (R&D) efforts, with Hisun obtaining exclusive global development and commercialization rights. Hertz will receive development milestone payments and a portion of sales profits upon commercialization.
HealZen’s Innovative Platform
HealZen Therapeutics has developed a proprietary protein degradation drug discovery platform called DaTProD. This platform is built on the world’s first DaELF tool library and is supported by DDT, ternary complex simulation, drug prediction, and other modules, enabling efficient PROTAC drug discovery. Core technologies include POI ligand, E3 ligand, and linker modules.
Advanced R&D Capabilities
The HealZen team has established a unique ELF library, featuring specialized sub-libraries such as Oral ELF, Long-Lasting ELF, and Tissue-enriched ELF. This has reshaped the R&D process for protein degrading drugs. The company is advancing more than 10 Category 1 drug candidates, with 3 in clinical stages and 2 pre-clinical candidates.-Fineline Info & Tech